Compositions, methods and products comprising human papillomavirus for detecting and treating a cancer
First Claim
Patent Images
1. A method of screening a patient for cancer, the method comprising:
- a) assaying for the presence of human papillomavirus in a sample from a biopsy taken from a patient, wherein the patient has been determined to be negative for CIN III, wherein said assaying comprises amplifying human papillomavirus gene sequences by use of a pair of primers to produce an amplified product, and probing said amplified product for the presence of a portion of an HPV sequence, wherein said pair of primers is either SEQ ID NO;
1 and SEQ ID NO;
2, or SEQ ID NO;
3 and SEQ ID NO;
4, and wherein presence of said HPV is indicative of breast cancer in said patient.
0 Assignments
0 Petitions
Accused Products
Abstract
Methods for screening a patient for a cancer wherein the methods comprise detecting an HPV in a biopsy from a patient are disclosed. Also disclosed are compositions and products for screening and for treating cancer in a patient, as well as methods of treating a patient afflicted with a cancer.
37 Citations
92 Claims
-
1. A method of screening a patient for cancer, the method comprising:
-
a) assaying for the presence of human papillomavirus in a sample from a biopsy taken from a patient, wherein the patient has been determined to be negative for CIN III, wherein said assaying comprises amplifying human papillomavirus gene sequences by use of a pair of primers to produce an amplified product, and probing said amplified product for the presence of a portion of an HPV sequence, wherein said pair of primers is either SEQ ID NO;
1 and SEQ ID NO;
2, or SEQ ID NO;
3 and SEQ ID NO;
4, andwherein presence of said HPV is indicative of breast cancer in said patient. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 11, 12, 13, 14, 15)
-
-
10. A method of screening a patient for cancer, the method comprising:
-
a) assaying for the presence of human papillomavirus in a sample from a biopsy taken from a patient wherein said assaying comprises amplifying human papillomavirus gene sequences by use of a pair of primers to produce an amplified product, and probing said amplified product for the presence of a portion of an HPV sequence selected from the group consisting of HPV18, HPV31, HPV 33, HPV35, HPV45, HPV58, wherein said pair of primers is either SEQ ID NO;
1 and SEQ ID NO;
2, or SEQ ID NO;
3 and SEQ ID NO;
4, andwherein presence of said HPV is indicative of breast cancer in said patient.
-
-
16-20. -20. (canceled)
-
21. A method of screening a patient for a cancer, the method comprising:
a) contacting cellular material with an HPV specific probe, wherein the cellular material is extracted from a biopsy taken from a patient, and wherein the patient has been determined to test negative for CIN III. - View Dependent Claims (22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32)
-
33. A method of screening a patient for a cancer, the method comprising:
a) contacting cellular material with a probe specific to a first HPV, and a second probe specific to a second HPV, wherein the cellular material is extracted from a biopsy taken from a patient and wherein the first HPV is HPV 16, and the second HPV is selected from the group consisting of HPV18, HPV31, HPV 33, HPV35, HPV45, HPV58. - View Dependent Claims (34, 35, 36, 37, 38, 39, 40, 41, 43)
-
42. A method of screening a patient for a cancer, the method comprising:
a) contacting cellular material with a probe specific to a HPV selected from the group consisting of HPV18, HPV31, HPV 33, HPV35, HPV45, HPV58, wherein the cellular material is extracted from a biopsy taken from a patient. - View Dependent Claims (44, 45, 46, 47, 48, 49, 50)
-
51. A method of treating a patient comprising:
a) administering a composition comprising an effective amount of an antisense HPV sequence to a patient. - View Dependent Claims (52, 53, 54, 55, 56)
-
57. A method of treating a patient comprising:
a) administering an effective amount of a composition to a patient, wherein the composition comprises an agent that inhibits expression of at least one HPV gene. - View Dependent Claims (58, 59, 60, 61, 62, 63)
-
64. A method of treating a patient comprising:
a) administering an effective amount of a composition comprising an agent that specifically inhibits the HPV16 E6 protein or the HPV16 E7 protein. - View Dependent Claims (65, 66, 67, 68)
-
69. A method of treating a patient comprising:
-
a) transfecting dendritic precursor cells of a patient with a recombinant viral vector that drives expression of an HPV antigen;
b) treating the dendritic precursor cells with a cytokine to produce dendritic cells stably expressing the HPV antigen;
c) contacting T cells together with the dendritic cells stably expressing the HPV antigen to produce primed T cells; and
d) administering to the patient an effective amount of either the primed T cells, dendritic cells, or a combination thereof. - View Dependent Claims (70, 71, 72, 73, 74, 75)
-
-
76. A kit for screening a patient for a cancer, the kit comprising:
a) a probe specific for detection of an HPV.
- 77. The kit of claim 77 wherein the probe is a single-stranded olidonucleotide sequence, a double-stranded oligonucletide sequence, a polypeptide, or any combination thereof.
-
80. A composition for treating a patient having a cancer, the composition comprising:
an effective amount of an HPV sequence. - View Dependent Claims (81, 82, 83, 84, 85, 86, 87)
-
88. A method of screening a patient for breast cancer, the method comprising:
-
a) assaying for the presence of human papillomavirus in a sample from a biopsy taken from a patient, wherein said assaying comprises amplifying human papillomavirus gene sequences by use of a pair of primers to produce an amplified product, and probing said amplified product for the presence of HPV 16 and a second human papillomavirus selected from the group consisting of HPV18, HPV31, HPV 33, HPV35, HPV45, HPV58, wherein said pair of primers is SEQ ID NO;
3 and SEQ ID NO;
4, andwherein presence of HPV 16 and said second human papillomavirus is indicative of breast cancer in said patient. - View Dependent Claims (89, 90, 91, 92)
-
Specification